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ABSTRACT 
 Sickle cell anemia is caused by a single mutation in the β-hemoglobin gene, HBB. 
The disease originated in Africa and affects millions of people worldwide. Sickle 
hemoglobin tetramers polymerize upon deoxygenation and lead to hemolysis and vaso-
occlusion. Patients with high fetal hemoglobin (HbF) can have milder disease. The only 
FDA-approved drug is hydroxyurea that increases HbF. HbF modulates the disease by 
preventing the polymerization of sickle hemoglobin and reduces the pain episodes, 
anemia, and organ damage associated with the disease. There are five common 
haplotypes associated with the HbS gene and that are very loosely associated with disease 
severity and HbF. Understanding the genetic bases of HbF regulation is a key factor to 
identify potential drug targets to induce HbF for therapeutic purposes. 
To fully understand the mechanism behind HbF regulation, developing a fast and 
accurate computational method for sickle cell haplotype classification is useful for 
examining the variability of HbF among sickle cell patients. Moreover, investigating the 
  viii 
cis and trans-acting regulators of HbF gene expression to pinpoint the mechanism 
through which they regulate HbF is essential to develop a successful treatment. The 
availability of high-throughput genetic data provides an excellent opportunity to study 
HbF regulation in sickle cell patients and normal people comprehensively.  
The work reported in this thesis describes a fast and accurate method for sickle cell HBB 
haplotype classification. I also examine the differential effect of cis and trans-acting HbF 
hemoglobin regulators on g-globin gene expression using the GTEx database and identify 
BCL2L1 as a new potential trans-regulator of HbF.  
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Chapter 1. Introduction 
 
Sickle cell anemia 
Sickle cell anemia is a genetic disorder of hemoglobin that is a result of homozygosity for 
a GAG-GTG mutation in the 6th position of the β-globin gene (HBB) that codes for sickle  
hemoglobin (HbS) (Ingram 1957). The disease affects millions worldwide and had its 
origins in Africa, the Middle East, and India (Flint et al. 1998; Kulozik et al. 1986). Upon 
deoxygenation, sickle hemoglobin tetramers polymerize and lead to many complications 
including hemolysis and vaso-occlusion as shown in Figure 1. Sickle cell anemia is 
characterized primarily by chronic anemia and periodic episodes of pain. The disease 
phenotypes are heterogeneous and have severe complications affecting the pulmonary, 
cardiovascular, renal, and other systems including lung injury, systemic and pulmonary 
hypertension, stroke, cutaneous leg ulceration, kidney injury, proteinuria, and 
osteonecrosis (Kato et al. 2017). At the moment, no cure is available other than by 
hematopoietic stem cell transplantation in rare patients.  Otherwise, treatment strategies 
include, blood transfusion, induction of fetal hemoglobin by hydroxyurea, management 
of vaso-occlusive crisis and chronic pain syndromes with analgesics, prevention and 
treatment of infections, and treating various organ damage syndromes associated with the 
disease like stroke and pulmonary hypertension(Piel et al. 2017). Allogeneic bone 
marrow transplantation (BMT) can cure sickle cell disease, BMT requires aggressive 
chemical intervention and about 5% of patients die with complications of transplantation; 
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the procedure is also very expensive and finding identical matched sibling donors is 
difficult (Walters  et al. 1996).   
 
Fetal hemoglobin in sickle cell anemia 
Fetal hemoglobin (HbF) is a well-known modulator of the pathophysiology of sickle cell 
disease (Habara and Steinberg 2016; Rees et al. 2010). HbF is mostly excluded from the 
deoxy sickle hemoglobin (HbS) polymer. This reduces the tendency of deoxyHbS to 
polymerize, in turn diminishing polymer-induced damage to the sickle erythrocyte and 
the many downstream consequences of this pathophysiologic event.  Patients with high 
levels of HbF can have milder disease, but HbF does not ameliorate equally all disease 
complications. This is a result of the complex pathophysiology of disease that is caused 
by sickle vaso-occlusion and intravascular hemolysis, each with a different effect on 
disease complications, and the variation in the distribution of the concentrations of HbF 
amongst HbF containing erythrocytes, or F-cells. The latter results in in varying red cell 
protection from the adverse effects of HbS polymerization because of the heterogeneous 
cellular concentrations of HbF (Kato et al. 2007; Steinberg et al. 2014). For example, 
high HbF is associated with fewer acute painful episodes but an effect of HbF on stroke is 
less apparent and patients with the same HbF concentration can have different disease 
severity because the distribution of HbF amongst erythrocytes is very different (Kato et 
al. 2017). Key to devising novel means of inducing therapeutically high levels of HbF is 
a detailed understanding of the mechanisms underlying the normal switch from HbF 
synthesis in the fetus to HbA synthesis in adults.  
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Hemoglobin switching in the b-globin gene cluster  
One feature of the transition from embryonic to fetal to extra-uterine life is the synthesis 
of globin polypeptides characteristic of each developmental stage. Switching in the HBB 
cluster is controlled by transcription factors that interact directly with these genes, or 
indirectly with other transcription factors to affect gene expression. Figure 2 displays the 
chromosomal order of the b-like globin genes and the associated cis-acting elements that 
contain binding sites for the trans-acting elements shown in Table 1 and in this figure 
(Cui et al. 2014; Cui et al. 2015; Ngo and Steinberg 2015). BCL11A, a major repressor of 
g-globin gene (HBG2, HBG1) transcription, has been intensively studied (Lettre and 
Bauer 2016; Sankaran et al. 2008; Sankaran and Weiss 2015; Zhou et al. 2010). 
Polymorphic variants in the erythroid-specific enhancers of this gene are being targeted 
using gene editing as a potential cell-based approach to increase HbF (Bauer et al. 2013). 
Recently BCL11A binding sites in the HBG promoters were presumed to be the key loci 
through which this transcription factor exerted its effects (Nan Liu 2017). 
Leukemia/lymphoma-related factor (LRF), encoded by ZBTB7A, another zinc finger 
transcription factor, is another important repressor of HBG transcription (Masuda et al. 
2016). ZBTB7A and BCL11A acted independently as HBG silencers and are parts of 
different nucleosome remodeling deacetylase (NuRD) complexes (Figure 2).  
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Figure 1. The pathophysiology of sickle cell disease as a result of mutation of glu6val 
which leads to polymerization of hemoglobin upon deoxygenation. The sickle polymer 
causes irreversible damage of erythrocytes, vasoocclusion and hemolysis (Steinberg 
2008). 
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Figure 2: Cis- and trans-acting effectors of gene expression within the β-globin gene 
cluster. The Ldb1 complex: (Ldb1/LMO2/GATA1/Tal 1) occupies the locus control 
region (LCR) and gene promoters and facilitates looping to globin gene promoters that 
could be modulated by cis-acting variants associated with HbS gene haplotypes. 
Throughout the HBB gene complex and its flanking regions are binding domains for 
BCL11A and ZBTB7A (LRF) shown as red and blue stars, respectively. Separate 
nucleosome remodeling deacetylase (NuRD) complexes are associated with BCL11A and 
LRF (ZBTB7A). MYB has a direct effect on HbF gene expression and also acts indirectly 
through KLF1 and BCL11A. Suppression of the HbF genes is depicted by dashed lines. 
This figure is not drawn to scale; based on Figure 3 from (Sankaran and Weiss 2015). 
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Transcript/Gene Effect Comment 
BCL11A Direct inhibition Master controller 
of HBG to HBB switching 
KLF1 Indirect 
inhibition 
Affects BCL11A 
MYB Indirect 
inhibition 
Affects KLF1 
LRF (ZBTB7A) Direct inhibition Causes active chromatin formation 
LSD1 Direct inhibition Silences the HBG promotor region 
ANTXR1a Inhibition Effects on HBG only hypothesized 
PPARGC1A (PGC-1α)b Direct induction Induces HBG with TR2 & TR4. 
Overexpression of PGC-1α has been 
shown to induce HBG in Lin- murine 
bone morrow cells. 
 
Table 1:  Some genes with established roles in HBG expression 
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ZBTB7A and Sickle Cell Anemia 
Fetal hemoglobin (HbF) is the major modulator of the phenotype of sickle cell anemia 
and increased concentrations can reduce disease severity.  HbF levels are controlled by 
genetic elements linked to the haplotype of the HBB gene cluster and by trans-acting 
quantitative trait loci (QTL). ZBTB7A (LRF) is a suppressor of γ-globin gene (HBG2, 
HBG1) expression. HbF levels were 70% after ZBTB7A knockout in a human erythroid 
cell line (HUDEP-2) that normally expressed adult HbA on terminal differentiation 
(Masuda et al. 2016). Knocking out both ZBTB7A and BCL11A increased HbF to more 
than 90% of total hemoglobin (Masuda et al. 2016). ZBTB7A and BCL11A acted 
independently as HBG silencers. In previous genome-wide association studies (GWAS) 
variants of ZBTB7A or in linkage disequilibrium (LD) with this gene were not associated 
with HbF (Lettre et al. 2008; Mtatiro et al. 2014; Ngo et al. 2013; Solovieff et al. 2010; 
Uda et al. 2008). Because of the profound effect of ZBTB7A on HbF expression we asked 
whether polymorphisms of this gene or its promoters and proximal enhancer elements, 
and in putative binding motifs for ZBTB7A in and adjacent to the HBB gene cluster are 
associated with HbF levels in sickle cell anemia. 
   
Genetic data from GWAS and next generation sequencing from diverse patients who 
were homozygous for the sickle hemoglobin gene and had varying levels of HbF were 
available for analysis (Table 2). Included were 21 individuals studied by whole genome 
sequencing (WGS) and 15 Saudi Benin and 8 Saudi AI haplotype homozygotes studied 
using exome sequencing   GWAS were available from 822 African American HbS 
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homozygotes of diverse haplotypes (Cooperative Study of Sickle Cell Disease or CSSCD 
cohort), 104 Saudi AI haplotype homozygotes who originated from the Eastern Province 
and 71 Saudi Benin haplotype homozygotes who originated from the Southwestern 
Province. GWAS data were also imputed to the 1000 Genomes (Phase 3) reference. All 
studies were approved by the Institutional Review Boards of the participating institutions. 
 
To detect variants in ZBTB7A and its promoters or putative proximal enhancers that 
might be associated with HbF we searched 100 kb upstream and 100 kb downstream of 
the ZBTB7A coding sequences using data from WGS. Using IMPUT2 the SNPs in this 
region were imputed to the 1000 Genomes (Phase 3) reference panel in the CSSCD and 
Saudi cohorts that were studied by GWAS in order to test associations of HbF with these 
variants using an additive genetic model. The most significant association with HbF in 
the CSSCD cohort did not pass the correction for multiple testing (rs114623325, p-value 
0.002).  Two of the 23 Saudi patients studied by exome sequencing with HbF levels of 
6.9% and 14.3% were heterozygous for a CGC insertion polymorphism (transcript 
NM_015898, c.539_540insCGC (p.Ala181_Ser182insAla) that appeared to be a neutral 
variant.  These data suggest that it is unlikely than common variants in ZBTB7A or its 
promoters and proximal enhancers accounted for HbF variation in sickle cell anemia. 
     
ZBTB7A affects HbF gene silencing through its binding in and about the HBB gene 
cluster.  Accordingly, using the permissive motif 
([GAC][ACG][GTAC][AC]CC[CAG][CTA]) as a target, we searched for variants in 
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these putative binding motifs in the interval downstream of OR51V1 (5’ olfactory 
receptor gene cluster) and upstream of OR51B4 (3’ olfactory gene cluster) flanking the 
HBB-like genes and its locus control region (LCR) in chromosome 11p15.5.  Within the 
putative binding motifs, we found 8 motif-modifying SNPs. The binding domains 
identified by bioinformatics analysis overlapped some of the ZBTB7A binding 
occupancy data based on ChIP-seq signals that were previously reported (Masuda et al. 
2016). Figure 3 displays the position of these SNPs in putative binding motifs along with 
the experimentally defined ZBTB7A occupancy regions.  Table 3 provides additional 
details of these SNPs. Rs16912979 is present in hypersensitive site (HS)-4 of the LCR; 
and rs7119428 and rs9736333, which are in perfect LD, are located in HS-2. The 
alternative allele (C) of both HS-2 SNPs, was present only in African American sickle 
cell anemia samples of diverse African-origin haplotypes and are in adjacent potential 
ZBTB7A binding sites at coordinates 11:5302080-5302087 and 11:5302057-11:5302064.  
HS-2 and HS-4 also contain GATA1 and TAL1 binding sites that were shown to be 
involved in hemoglobin switching. The alternative C allele of rs7119428 that was found 
in HS-2 had a minor allele frequency of about 0.22 in the HapMap Yoruban sample and 
0.17 in another African population reported in dbSNP; the major A allele was 
monomorphic in Europeans, Asians and Indians as reported in dbSNP. Rs7119428, which 
was not represented on the Human610-Quad array (~600,000 SNPs), was imputed with 
very high confidence in cohorts studied with this chip (Table 2). The C allele had a 
frequency of 0.56 in 822 cases of the African American CSSCD cohort, in which all HBB 
haplotypes except for the AI haplotype were represented. This SNP was included on the 
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Illumina Human Omni Express BeadChip (~700,000 SNPs). Its allele frequency was 0.88 
in Saudis with the Benin haplotype who were studied using this chip. There was a 
significant association of this variant with HbF in the CSSCD cohort after adjusting for 
age and sex (beta coefficient = -0.05, p-value 0.02) but the effect was small. In 15 Saudi 
patients with the Benin haplotype who were heterozygous for the C allele, HbF was 
13.7%; 85 C homozygotes had HbF of 10.2% however this difference was not significant 
(p-value 0.14). These preliminary results suggest that the C alleles of both rs7119428 and 
rs9736333 in HS-2, and also other SNPs in LD with these alleles might be play some role 
in the decreased HbF in sickle cell anemia of African descent compared with AI 
haplotype sickle cell anemia. Although rs7119428 was rare in Saudi AI sickle cell anemia 
we found 3 heterozygotes for the C allele and their HbF was about 10% compared with 
nearly 20% in homozygotes for the common A allele.   
 
A putative ZBTB7A binding motif was found 5’ to HBG2 although this region was 
devoid of uniquely mapped binding sites as reported in (Masuda et al. 2016). This motif 
contained rs7482144 (G/A) in the positive strand or (C/T) in the negative strand, the 
well-studied Xmn1 restriction site that is associated with high HbF in the African Senegal 
and AI haplotypes (Nagel et al. 1985). Variants were also present in HBG1 and HBB. The 
T allele of rs567305547 and rs537552941 in the small intron of HBG1, with an 
alternative allele frequency of about 0.40 in Africans, was found in 2 of 3 African Benin 
haplotype samples studied with WGS.  All AI haplotype patients were monomorphic for 
the G allele, a result confirmed by Sanger sequencing in a subset of cases.  These 2 
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intronic SNPs were not on the haplotype reference panel used for imputation and 
therefore they could not be imputed so any association with HbF could not be tested. 
 
SNPs in putative ZBTB7A binding sites distinguish the high HbF AI haplotype from 
African origin haplotypes of sickle cell anemia where HbF is usually lower. They are 
present in sites with characteristics of active enhancers like transcription factor binding 
and epigenetic marks and are therefore candidates for the functional elements of this 
haplotype. Perhaps the variants of this haplotype alter looping of the LCR to globin gene 
promoters, however mechanistic studies are required to validate these genetic 
associations.  
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Cohorts n Age (y) HbF (%) 
Saudi Benin Haplotype-Exome-Seq 15 21.5±10.5 9.8±3.7 
Saudi Benin Haplotype-GWAS (700K) 100 18.6±11.0 10.8±4.6 
African American Benin-WGS 3 26.0±3.6 19.8±0.4 
African American Senegal- WGS 1 5.9 16.0 
Saudi AI Haplotype-Exome-Seq 8 32.3±11.1 12.7±5.5 
Saudi AI Haplotype cohort 1-GWAS(600K) 42 26.4±11.1 17.6±5.018 
Saudi AI Haplotype cohort 2-GWAS(700K) 62 23.9±9.6 18.8±7.5 
Saudi AI Haplotype-WGS 7 25.9±6.8 23.5±2.6 
Saudi AI Haplotype-WGS 7 34.1±10.3 8.2±1.3 
Indian AI haplotype-WGS 3 22.7±5.5 26.0±4.5 
CSSCD-GWAS (600K) 822 13.6±11.3 5.2±5.6 
  
Table 2. Cohorts analyzed. Fourteen Saudi and 3 Indian AI haplotype HbS homozygotes, 
3 African Americans with the Benin haplotype (selected because of their unusually high 
HbF) and 1 African American with the Senegal haplotype had whole genome sequencing 
(WGS). Saudi AI patients who had WGS all had the same minor alleles for BCL11A and 
MYB. The other cohorts included African Americans of diverse HBB haplotypes who 
were participants in the Cooperative Study of Sickle Cell Disease (CSSCD) and Saudi 
patients with the AI and Benin haplotype. The approximate number of variants 
represented on the 2 Illumina arrays used for genome-wide association studies (GWAS) 
is shown in parentheses.  
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Site Location (v37) S Ref-seq Benin Senegal AI RSID REF allele 
ALT 
allele 
HS-4 11:5309693-5309700 
+ GGTC
CCCA 
GGCCC
CCA 
GGCC
CCCA 
GGTCC
CCA rs16912979 T C 
HS-2 11:5302080-5302087 
- AGGG
GCCT 
CGGG
GCCT 
AGGG
GCCT 
AGGG
GCCT rs7119428 A C 
HS-2 11:5302057-5302064 
- GGGG
GTGG 
GGGG
GCGG 
GGGG
GTGG 
GGGG
GTGG rs9736333 T C 
HBG2 5' 11:5276167-5276174 
+ GGGA
CCGT 
GGGA
CCGT 
GGAA
CCGT 
GGAA
CCGT rs7482144 G A 
HBG1  
intron 1 
11:5270900-
5270907 
- 
AGGG
TCCT 
AGTTT
CCT 
AGGG
TCCT 
AGGG
TCCT 
rs56730554
7 
rs53755294
1 
G T 
HBG1 
intron 2 
11:5269931-
5269938 
+ GCCA
CCAT 
GCCAC
CAT 
CCCAC
CAT 
CCCAC
CAT rs2187608 G C 
HBB 
intron 2 
11:5247791-
5247798 
+ CGTCC
CAT 
GGTCC
CAT 
GGTCC
CAT 
GGTCC
CAT rs10768683 C G 
 
 
Table 3. SNPs in putative ZBTB7A binding motifs in the HBB gene cluster (RSID) along 
with their genomic locations (v37), reference sequence (ref-seq and variation according 
to haplotype (Benin, Senegal, AI). Underlined and bolded are the variant alleles. S 
denotes positive (+) or negative (-) strand location of the putative binding motif.  
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Figure 3. Approximate locations of the putative binding motifs for ZBTB7A (first track) 
that contained polymorphisms (shown above track) and were located between OR51V1 in 
the 5’ olfactory receptor gene cluster and OR51B4 in the 3’ olfactory gene cluster 
flanking the HBB-like genes and its locus control region (LCR) on chromosome 11p15.5.  
SNPs in the binding motifs are shown (arrows) with their major/alternative alleles. ChIP-
seq data (tracks 2 and 3) is taken from (Masuda et al. 2016) along with the relative 
locations of globin genes and the LCR (track 4).  Extensive homology between HBG2 
and HBG1 makes mapping to these regions difficult and ChIP-seq data only showed 
uniquely-mapped binding in HBG1 (track 3) 
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Haplotypes of the HbS gene and HbF  
The first suggestion that the cis-acting elements of the HBB gene complex influenced 
HbF levels was the discovery that the HbS gene originated on five common HBB 
haplotypes. Although each haplotype was associated with a characteristic average level of 
HbF (Akinsheye et al. 2011; Bhagat et al. 2013; Ngo et al. 2013), among patients 
homozygous for any haplotype, HbF levels varied. The AI haplotype was prevalent in 
patients from the Arabian Peninsula and in India and might have originated in India and 
migrated to the Arabian Peninsula. It is associated with the highest HbF level of all 
haplotypes. After HbF levels stabilized at about age 10 years, adults with the AI 
haplotype had an average HbF level approaching 20%.  Four other common HBB 
haplotypes, the Senegal, Benin, Cameroon and Bantu or Central African Republic 
haplotype originated in Africa. These were associated with mean HbF levels of 10%, 7%, 
7%, and 5%, respectively; in these patients HbF levels become stable after five years of 
age (Chang et al. 1995; Green et al. 1993). 
 
HBB haplotypes were first categorized by examination of a limited number of restriction 
endonuclease cleavage sites, most of which are SNPs. With one exception, little evidence 
existed that any of these polymorphisms were functionally important. The exception was 
the Xmn1 restriction site polymorphism (rs7482144), located in the promoter of HBG2, 
158 bp upstream of the transcription start site. This SNP was exclusive to carriers of the 
AI and Senegal haplotypes. Resequencing part of the HBB gene cluster suggested that 
rs10128556, a SNP in linkage disequilibrium (LD) with rs7482144, was the functional 
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element of the Senegal haplotype (Galarneau et al. 2010). However, a mechanism 
whereby the locus of this SNP influenced HbF was unclear, and unlike rs7482144, this 
SNP was not present in a putative transcription factor binding site (Figure 3). 
 
To fully understand the mechanism behind HbF regulation, developing a fast and 
accurate method for haplotype classification is crucial as well as studying the cis and 
transacting elements that regulate expression of HbF. This dissertation will cover the 
major projects: 
1. Developing a fast and accurate method for classifying sickle cell HBB haplotypes. 
2. Studying the genetic determinants of HbF in Saudi Arabian and African Benin 
haplotype sickle cell.  
3. Investigating cis and trans-acting regulators of HbF expression to identify 
quantitative trait loci associated with HBG expression on a genome-wide scale. 
 
Understanding the genetic bases of HbF expression is a key element in developing 
therapeutic agents. Achieving the goals of these projects will give the medical 
community a better understanding of HbF genetic modulators, and might lead to the 
identifications of potential drug targets or drug candidates. 
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Chapter 2. A Phased SNP-based Classification of Sickle Cell Anemia HBB 
Haplotypes 
 
Background 
Haplotypes of sickle cell anemia were first ascertained by analysis of restriction fragment 
length polymorphisms (RFLPs) in the HBB gene cluster (Sutton et al. 1989). 
Classification of patients’ haplotype is useful for prognostic purposes and for studying 
the genetic differences that contribute to the HbF variability among these haplotypes. 
RFLP classification was based on detecting whether or not cleavage occurred at five to 
eight restriction sites when DNA was digested with restriction endonucleases, as shown 
in Figure 4 (Antonarakis et al. 1982; Joly et al. 2011; Rezende et al. 2016). This method 
is time-consuming and can lead to error (Joly et al. 2011). Fluorescence resonance energy 
transfer coupled with high-resolution melting (HRM) assay is another method to classify 
sickle cell haplotypes, but it is also labor intensive and requires multiple laboratory 
assays (Joly et al. 2011). Neither method is capable of differentiating between parental 
and maternal alleles in an individual so that without informative genetic data from family 
members, the phasing of restriction patterns is not possible, and in many cases 
ascertainment of a haplotype is either equivocal or impossible. We used genome-wide 
association study (GWAS) data imputed to a reference panel to obtain a phased output. 
The phased GWAS data allowed assigning SNPs to parental chromosomes, which 
facilitated the classification procedure using fewer SNPs.  
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Methods 
Haplotype Classification 
GWAS data were available for patients with sickle cell anemia from the CSSCD 
(Solovieff et al. 2010). SNP array data containing 588451 markers were evaluated using 
PLINK to identify and remove SNPs with minor allele frequency (MAF) < 0.01, violated 
Hardy-Weinberg Equilibrium (HWE), and had more than 0.05 missing genotype 
information (Purcell et al. 2007). Genotypes for a total of 560170 SNPs were imputed 
using the Michigan Imputation Server (Das et al. 2016), the 1000 Genomes Phase 3 v5 
reference panel, and the Eagle phasing algorithm to obtain phased output (Loh et al. 
2016; The Genomes Project 2015). We developed a Python script based on VCF and 
PYSAM Python modules to read SNP information and assign the haplotype accordingly 
(Casbon 2017; Pysam-developers/pysam.). Code and an example are available on GitHub 
(https://github.com/eshaikho/haplotypeClassifier). We used this script to classify 1394 
samples that were previously classified by RFLP in the CSSCD. We selected four SNPs 
(rs3834466, rs28440105, rs10128556, and rs968857) which define all of the haplotypes 
spanning the β-globin gene cluster (Table 4). 
 
Calculation of HbF Average per Haplotype 
To check the consistency of classification and average HbF for each haplotype, we used 
samples with available HbF level information including 559 of the 813 samples that were 
successfully classified with RFLPs, 916 of the samples classified with the SNP-based 
method, and 252 samples that were either partially classified or failed classification with 
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RFLPs. We calculated the average HbF level for each haplotype using psych R package 
(Revelle 2017), and generated a boxplot for the most common haplotypes (Benin 
homozygotes [BEN/BEN], Benin/Central African Republic compound heterozygotes 
[BEN/CAR], Benin/Senegal compound heterozygotes [BEN/SEN], Benin/Cameroon 
compound heterozygotes [BEN/CAM], Central African Republic homozygotes 
[CAR/CAR]) in this cohort to show the consistency of HbF levels across the three groups 
(five RFLP classification, SNP-based classification, and the group that failed five RFLP 
classification but were able to be classified with the SNP-based method). 
 
Classification of haplotypes in Saudi sickle cell anemia patients and in a library of 
sickle cell anemia induced pluripotent stem cells (iPSCs) 
Since CSSCD patients are mostly African American, we tested our method using data 
obtained from sickle cell anemia patients from the Eastern and Southwestern Provinces of 
Saudi Arabia. Eastern Province patients tend to have the autochthonous AI haplotype as 
the major haplotype, while Southwestern Province patients mostly have the BEN 
haplotype that was introduced from Africa. The HbF levels in Saudi Benin patients is 
twice as high as African American patients with this haplotype (Akinsheye et al. 2011; 
Alsultan et al. 2011). To further test our method on a mixed population of diverse 
ethnicity we reclassified haplotypes originally ascertained using RFLPs in a library of 
sickle cell anemia-derived iPSCs (Park et al. 2017). 
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Results 
Haplotype Classification 
Of 371 CSSCD patients classified as BEN/BEN using five RFLPs, we achieved a 
concordance of 98% (367/371) using four phased SNPs. We achieved >99% concordance 
for patients classified as BEN/CAR using RFLPs. For BEN/SEN, BEN/CAM, 
CAR/CAR, CAR/SEN, CAR/CAM, CAR/AI, SEN/SEN, SEN/CAM, SEN/AI, and 
CAM/CAM haplotypes our concordance with the RFLP method was 100% although the 
numbers of patients in each category was smaller. Two patients classified originally as 
BEN/AI failed reclassification (Table 5). Discordance between our method and the five 
RFLP method occurred in only eight of 813 patients providing an overall concordance 
rate >99%. Two patients classified as BEN/AI with RFLP were reclassified as 
UNKNOWN/SEN. Four patients classified as BEN/BEN were reclassified as 
UNKNOWN/BEN, CAR/CAR, CAM/BEN, and SEN/BEN. The last two patients were 
classified as CAR/SEN and SEN/BEN with our methods instead of BEN/CAR according 
to RFLP analysis. Importantly, we were able to assign a haplotype to 86% (343/ 395) of 
samples CSSCD that failed classification using RFLPs.  
 
Calculation of HbF Average per Haplotype 
The average haplotype HbF level of patients classified with our method is consistent with 
average HbF in haplotypes reported in literature based on RFLPs (Table 6) (Perrine et al. 
1972; Powars 1991).  The average haplotype HbF for samples unclassifiable using 
RFLPs, but classified using phased SNP data matched the average HbF for each known 
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haplotype (Table 6). Boxplots of the most common five haplotypes in the CSSCD cohort 
show the consistency of HbF levels across the three classification groups (Figure 5).  
 
Classification of Haplotype in Saudi Sickle Cell Anemia and Sickle iPSCs 
Haplotypes among 55 Southwestern Province patients classified using the RFLP method 
included 39 BEN/BEN, 11 CAR/CAR, 2 BEN/SEN, 1 BEN/CAR, 1 SEN/SEN and one 
unknown. The distribution of haplotypes for these subjects derived using the SNP method 
was 48 BEN/BEN, 3 BEN/UNKNOWN, 2 BEN/CAM, and one AI/AI (Table 6).  The 
concordance between RFLP and SNP-based classification was 67%. For the 30 Eastern 
Province patients, we had 100% concordance since all patients reclassified as AI/AI 
(Table 6).  
 
In a library of sickle cell anemia iPSCs there was high concordance between the two 
methods of haplotype ascertainment. The only discordance was in two patients classified 
originally as BEN/BEN that according to SNP-based reclassification were CAM/BEN 
and CAR/SEN (Table 7). Importantly, we were able to assign a haplotype to 15 of 17 
iPSC samples that were classified as either atypical or were indeterminate using RFLPs. 
Discussion  
In adults, homozygotes for the BEN, CAR, and CAM haplotypes were associated with 
HbF of 5-7% of total hemoglobin; SEN and AI haplotypes had HbF levels of about 10% 
and 20%, respectively. Using GWAS data we were able to classify with high accuracy 
and time efficiency the haplotype of sickle cell anemia patients using four SNPs. The 
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primary feature of our classification method is a phasing step after genotype imputation 
where SNP alleles are assigned to parental chromosomes, and the haplotype of each 
chromosome is assigned independently. This method was superior to ascertaining 
haplotype by RFLP using unphased SNPs at five sites and was successfully applied in a 
few seconds on a personal computer.  
 
Haplotyping errors can occur using the SNP-based method because of the SNP 
genotyping platform, imputation errors, and ambiguities arising from phasing algorithms. 
Nevertheless, in African-origin patient samples, we were able to achieve a concordance 
of 99% percent (805/813) between 4-SNP haplotypes derived from a phasing algorithm 
using GWAS data with 5-SNP haplotypes determined using restriction analysis. 
Haplotype assignment in a sickle cell anemia iPSC library also showed high concordance 
and demonstrated the efficiency of SNP-based method to classify samples that failed 
RFLP classification. The discordance between SNP-based and RFLP ascertainment most 
likely resulted from errors in the RFLP classification that is sensitive to the presence of 
other SNPs in the restriction sites and the vagaries of restriction enzyme analysis and 
Southern blotting that was used for haplotype analysis in the CSSCD.   
In 30 Saudi East patients where the AI haplotype was ascertained by genotyping 
rs7482144 (Xmn1 5′ to HBG2), rs3834466 (Hinc2 5′ to HBE1), and rs549964658 (5′ to 
HBD) we had 100% concordance. The major discordance between RFLP and SNP-based 
analysis for classification of Saudi Southwestern patients occurred among 11 subjects 
classified as CAR/CAR.  Eight of these 11 were reclassified as BEN/BEN and three as 
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BEN heterozygotes. The only difference between CAR and BEN haplotypes is the SNP 
rs968857 at the HincII site 5’ of HBD (Figure 4, Table 4).  It is most likely that this 
discrepancy was a result of an error in RFLP analysis. If the discordance was due to 
imputation quality, the error rate would probably match the imputation error. There is 
100% discordance at this HincII site while the imputation quality score of rs968857 is 
R2=0.99. One patient with HbF of 20.4% originally as SEN/SEN by RFLP was 
reclassified as AI/AI.  
 
To investigate the discordance in Southwestern Province patients, we examined the 
genotype data of the HBB gene cluster downstream of OR51V1 (5’ olfactory receptor 
gene cluster) and upstream of OR51B4 (3’ olfactory gene cluster) in both patient groups. 
The SNP genotypes of the 11 CAR/CAR that we reclassified as BEN/BEN or BEN 
heterozygous had the same SNP genotype of BEN/BEN patients that were classified as 
such with both methods. The genotype data, average HbF, and the imputation quality 
score of rs968857 suggest that the high discordance in Southwestern Saudi patients is due 
to RFLP errors.  
 
A limitation of our method is the dependency on the availability of GWAS data 
for many SNPs in the β-globin gene region. However, many large patient cohorts have 
been genotyped using genome-wide SNP arrays and the cost of a gene array is less than 
the cost of genotyping by RFLP.  In these patients, haplotype information might be useful 
as a covariate in a genetic risk analysis. RFLP analysis might be suitable for a small 
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number of patients but requires optimization of all of the individual assays. The main 
advantage of our haplotype determination method is the rapid classification and high 
accuracy. This method can also be used for whole genome sequence data classification 
after SNP calling and phasing. Moreover, it is not sensitive to SNPs that alter the 
restriction enzyme recognition sequence that can lead to error using RFLPs 
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Figure 4. Restriction Enzyme Recognition Sites in the b-Globin Gene Cluster. RSIDs of 
SNPs present in restriction endonuclease sites in the b-globin-like gene cluster. (+) 
denotes the presence of the corresponding enzyme site while (-) denotes the absence in 
the five-major sickle cell haplotype (Benin (BEN), Central African Republic (CAR), 
Senegal (SEN), Cameroon (CAM) and Arab–Indian (AI). 
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Figure 5. Boxplots of the Common Haplotypes in the CSSCD. Shown are the HbF levels 
according to haplotype defined by RFLPs and SNP-based methodology. The third panel 
shows data from patients not classified by RFLP but successfully classified using the 
SNP-based method. The black dots in the middle of the boxplots represent mean HbF 
level, while the black horizontal lines represent the median HbF level. 
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Haplotype	 rs3834466	 rs28440105	 rs10128556	 rs968857	
AI GT	 C	 T	 T	
SEN G	 C	 T	 T	
BEN G	 C	 C	 T	
CAR G	 C	 C	 C	
CAM G	 A	 C	 T	
 
Table 4. Five Major Haplotypes and Alleles of the four SNPs defining the haplotype. 
  
  
  
28 
Haplotype	 	5	RFLPs		 4	SNPs	 Concordance	
BEN/BEN 371	 367	 0.989218329	
BEN/CAR 226	 224	 0.991150442	
BEN/SEN 91	 91	 1	
BEN/CAM 41	 41	 1	
CAR/CAR 31	 31	 1	
CAR/SEN 17	 17	 1	
CAR/CAM 14	 14	 1	
SEN/CAM 9	 9	 1	
SEN/SEN 8	 8	 1	
BEN/AI 2	 0	 0	
CAR/AI 1	 1	 1	
SEN/AI 1	 1	 1	
CAM/CAM 1	 1	 1	
 
Table 5. Comparison of Haplotype Classification Methods for 813 Sickle Cell Anemia 
Patients from the CSSCD. 5 RFLP represents haplotypes previously assigned by RFLPs 
using information from 5 restriction sites based on Southern blotting. 4 SNPs represents 
the number of haplotypes assigned using the phased SNP-based classification.  
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Table 6. Mean HbF Levels Among Haplotypes.  Included are 559 patients with HbF 
phenotypes classified with RFLP method, 916 patients with HbF phenotypes classified 
with SNP-based method, and 252 samples that failed RFLP classification but were 
classifiable with SNP-based method. (n) is the number of patients in the corresponding 
haplotype class, (mean) is the mean of HbF per haplotype, (sd) is the standard deviation.  
* CSSCD are African Americans; ** SW Saudi is Saudi patients from Southwestern 
Province; ***E Saudi are Saudi patients from the Eastern Province. UNK-unknown 
	 	 *CSSCD	 	
	 RFLP	classification	 SNP-based	classification	 Failed	RFLP	classification	
Haplotype	 n	 mean	 sd	 n	 mean	 sd	 n	 mean	 sd	
BEN/BEN	 253	 6.69	 5.58	 379	 6.39	 5.14	 89	 6.07	 4.32	
BEN/CAR	 157	 7.32	 7.63	 261	 7.04	 6.77	 74	 6.83	 5.37	
BEN/SEN	 62	 8.18	 4.75	 116	 7.99	 5.32	 33	 7.72	 5.50	
BEN/CAM	 32	 4.81	 3.89	 53	 5.33	 5.19	 15	 6.06	 6.18	
CAR/CAR	 21	 5.52	 3.71	 41	 5.59	 3.90	 16	 5.66	 4.47	
CAR/SEN	 11	 9.80	 3.48	 24	 8.91	 7.59	 7	 11.24	 13.14	
CAR/CAM	 9	 3.80	 2.51	 18	 3.96	 3.24	 8	 4.41	 4.16	
SEN/SEN	 7	 9.24	 5.30	 13	 8.74	 4.35	 5	 7.58	 3.35	
CAM/SEN	 3	 7.43	 6.23	 9	 8.61	 6.02	 5	 9.24	 7.17	
BEN/AI	 2	 4.20	 5.37	 -	 -	 -	 -	 -	 -	
CAM/CAM	 1	 7.00	 -	 1	 7.00	 -	 -	 -	 -	
CAR/AI	 1	 16.10	 -	 1	 16.10	 -	 -	 -	 -	
	 	 	 	 	 **SW	Saudi	 	 	 	 	
	 RFLP	classification	 SNP-based	classification	 Failed	RFLP	classification	
Haplotype	 n	 mean	 sd	 n	 mean	 sd	 n	 mean	 sd	
BEN/BEN		 39	 11.22	 5.32	 48	 10.28	 4.19	 -	 -	 -	
CAR/CAR	 11	 9.35	 5.07	 -	 -	 -	 -	 -	 -	
BEN/SEN		 2	 8.65	 0.64	 -	 -	 -	 -	 -	 -	
BEN/CAR	 1	 6.50	 -	 1	 3.10	 -	 -	 -	 -	
SEN/SEN	 1	 20.40	 -	 -	 -	 -	 -	 -	 -	
UNK	 1	 12.60	 -	 -	 -	 -	 -	 -	 -	
AI/AI	 -	 -	 -	 1	 20.40	 -	 -	 -	 -	
BEN/CAM	 -	 -	 -	 2	 10.15	 9.69	 -	 -	 -	
BEN/UNK	 -	 -	 -	 3	 20.20	 8.64	 -	 -	 -	
	 	 ***E	Saudi	 	
	 RFLP	classification	 SNP-based	classification	 Failed	RFLP	classification	
Haplotype	 n	 mean	 sd	 n	 mean	 sd	 n	 mean	 sd	
AI/AI	 30	 18.03	 5.39	 30	 18.03	 5.39	 -	 -	 -	
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Name	of	Line	 Gender	 Nationality	of	Origin	 Age	 Haplotype	 4SNPs	
SA108	 male	 Saudi	Arabia	 9	 AI/AI	 AI/AI	
SA50-1	 female	 Saudi	Arabia	 NA	 AI/AI	 AI/AI	
SA106-1	 female	 Saudi	Arabia	 NA	 AI/AI	 AI/AI	
SA170-1	 male	 Saudi	Arabia	 3	 AI/AI	 AI/AI	
SS2-1	 female	 US	 32	 UNK/UNK	 BEN/SEN	
SS2-1GAG	(CRISPR	corrected)	 female	 US	 32	 UNK/UNK	 BEN/SEN	
SS12-1	 female	 US	 27	 UNK/UNK	 BEN/CAR	
SS18-1	 female	 US	 23	 UNK/UNK	 UNK/UNK	
SS28-1	 female	 US	 25	 UNK/UNK	 BEN/BEN	
SS36	 male	 US	 38	 UNK/UNK	 BEN/CAR	
SS41-1	 male	 US	 21	 UNK/UNK	 CAR/CAR	
SS45-1	 female	 US	 37	 UNK/UNK	 BEN/BEN	
SS47-1	 female	 US	 42	 UNK/UNK	 BEN/CAR	
SS48-1	 male	 US	 30	 UNK/UNK	 CAR/CAR	
SA5-1	 female	 Saudi	Arabia	 9	 UNK/UNK	 BEN/BEN	
SA53-1	 male	 Saudi	Arabia	 14	 UNK/UNK	 BEN/CAR	
SA208	 male	 Saudi	Arabia	 7	 UNK/UNK	 UNK/BEN	
SA138-1	 male	 Saudi	Arabia	 16	 UNK/UNK	 AI/AI	
BR-SP-21-1	 female	 Brazil	 20	 UNK/UNK	 BEN/CAR	
BR-SP-37-1	 female	 Brazil	 20	 UNK/UNK	 CAR/CAM	
BR-SP-45-1	 female	 Brazil	 20	 UNK/UNK	 CAR/CAR	
SS24-1	 male	 US	 24	 CAR/CAR	 CAR/CAR	
SS25-1	 female	 US	 22	 CAR/CAR	 CAR/CAR	
BR-SP-3-1	 female	 Brazil	 34	 CAR/CAR	 CAR/CAR	
BR-SP-23-1	 female	 Brazil	 23	 CAR/CAR	 CAR/CAR	
BR-SP-25-1	 male	 Brazil	 34	 CAR/CAR	 CAR/CAR	
BR-SP-41-1	 male	 Brazil	 22	 CAR/CAR	 CAR/CAR	
BR-SP-43-1	 male	 Brazil	 21	 CAR/CAR	 CAR/CAR	
SS9-1	 female	 US	 29	 BEN/CAR	 BEN/CAR	
SS13-1	 female	 US	 25	 BEN/CAR	 BEN/CAR	
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Table 7. Sickle Anemia-Specific iPSC Library. Haplotype denotes the haplotype 
classification and 4 SNPs is SNP-based reclassification. The table is modified from (Park 
et al. 2017). 
SS15-1	 female	 US	 28	 BEN/CAR	 BEN/CAR	
SS35	 male	 US	 50	 BEN/CAR	 BEN/CAR	
BR-SP-29-1	 male	 Brazil	 20	 BEN/CAR	 BEN/CAR	
BR-SP-33-1	 female	 Brazil	 53	 BEN/CAR	 BEN/CAR	
BR-SP-39-1	 male	 Brazil	 22	 BEN/CAR	 BEN/CAR	
SS5-1	 male	 US	 32	 BEN/BEN	 BEN/BEN	
SS14-1	 female	 US	 39	 BEN/BEN	 BEN/BEN	
SS16-1	 female	 US	 36	 BEN/BEN	 BEN/BEN	
SS19-1	 male	 US	 30	 BEN/BEN	 BEN/BEN	
SS29-1	 female	 US	 32	 BEN/BEN	 BEN/BEN	
SS32	 female	 US	 33	 BEN/BEN	 BEN/BEN	
SS37	 female	 US	 37	 BEN/BEN	 BEN/BEN	
SS38	 male	 US	 26	 BEN/BEN	 BEN/BEN	
SS44-1	 female	 US	 23	 BEN/BEN	 BEN/CAM	
SS49-1	 male	 US	 31	 BEN/BEN	 CAR/SEN	
SA36	 female	 Saudi	Arabia	 26	 BEN/BEN	 BEN/BEN	
SA40-1	 male	 Saudi	Arabia	 20	 BEN/BEN	 BEN/BEN	
SA64	 male	 Saudi	Arabia	 14	 BEN/BEN	 BEN/BEN	
SA82-2	 male	 Saudi	Arabia	 24	 BEN/BEN	 BEN/BEN	
SA209-1	 male	 Saudi	Arabia	 12	 BEN/BEN	 BEN/BEN	
SA210-1	 male	 Saudi	Arabia	 9	 BEN/BEN	 BEN/BEN	
BR-SP-31-1	 male	 Brazil	 35	 BEN/BEN	 BEN/BEN	
SS4-1	 male	 US	 30	 BEN/SEN	 BEN/SEN	
SS8-2	 female	 US	 31	 SEN/SEN	 SEN/SEN	
SS43-2	 female	 US	 32	 SEN/SEN	 SEN/SEN	
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Chapter 3. Genetic Determinants of HbF in Saudi Arabian and African Benin 
Haplotype Sickle Cell Anemia 
Background 
 
 Each of the five major haplotypes of the HBB gene cluster (Benin, Car, 
Cameroon, Senegal, and AI) in sickle cell anemia are associated with different HbF 
levels. Although HbF is the major modulator of disease severity, the genetic elements 
that underlie the association of HbF and HBB haplotypes are not fully understood 
(Steinberg et al. 2009). 
 
Saudi sickle cell patients from the Southwestern Province, whose HBB gene cluster is of 
African origin, have HbF levels of about 10%; African origin patients with the Benin 
haplotype have HbF levels of about 6%.  Saudi patients have a genetic population 
structure similar to other Arabs, which does not resemble African-origin patients 
(Alsultan et al. 2011). We hypothesized that while Saudi and African American Benin 
haplotype homozygotes have similar HBB clusters, there might be common variants in 
the Saudi Benin patients that are associated with their increased HbF; conversely, African 
American Benin patients might have common variants that are associated with reduced 
HbF relative to Saudi patients. 
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Methods 
To study the genetic differences between Saudi and African American Benin haplotype 
patients that might be associated with HbF, we imputed genome-wide association study 
(GWAS) data from the CSSCD and patients from the Southwestern Province of Saudi 
Arabia to 1000 Genomes Phase 3 v5 reference panel. Pre-imputation quality control was 
performed using PLINK (Purcell et al. 2007), and imputation was carried out through the 
Michigan Imputation server and phased imputed data was obtained using Eagle (Loh et 
al. 2016). We classified haplotypes using haplotypeClassifier available from 
https://github.com/eshaikho/haplotypeClassifier. Only homozygous Benin haplotype 
cases were selected for downstream analysis. We then removed related samples and 
outliers (based on their genetic markers) in the first 20 principal components (PCs) using 
King and EIGENSOFT, respectively (Manichaikul et al. 2010; Patterson et al. 2006). 
There were 293 African American patients not taking hydroxyurea, 153 males, and 140 
females, aged between 2 and 68 years with an average HbF of 6.38%, and 63 Saudi 
Benin haplotype patients 27 of them are taking hydroxyurea, 36 males and 27 females, 
aged between 4 and 43 years, with an average HbF of 10.38%. A linear model adjusted 
for age and sex to predict the effect of PCs HbF level showed insignificance of the first 
20 components indicating absence of population substructure within each population; the 
first five PCs were used in the final GWAS analysis to account for any potential bias due 
to these components. Log10 HbF levels were employed as a quantitative phenotype to find 
the most significant SNPs in each cohort. Efficient and Parallelizable Association 
Container Toolbox (EPACTS; https://github.com/statgen/EPACTS) adjusted for sex and 
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the first five PCs were used for the final analysis. To avoid false associations due to small 
sample size we only considered SNPs with minor allele frequency (MAF) greater than 
0.05. Including age as covariate does not improve the goodness of the model fit, thus it 
was excluded from the final model. Both cohorts were analyzed separately, and subjected 
to the same analytical methods except for hydroxyurea adjustment in Saudi Benin 
patients.  
 
Results and Discussion 
In Saudi Benin cases, there were no associations with HbF meeting GWAS significance 
levels; however, the small sample size reduced the statistical power of the study to detect 
an association (Figure 6 & Table 8). In African American Benin haplotype patients, only 
rs1427407 in BCL11A met GWAS significance levels for association with HbF (Figure 
7). Six intronic SNPs in BCL11A had marginal genome-wide significance; 3 intronic 
SNPS in LARGE1, NEDD9 and PAK2 also showed marginal GWAS significance with p-
values between 8.97E-07 and 2.61E-07 (Table 9). The allele frequencies for the top 10 
associated SNPs in African American patients were similar to that in Saudi patients 
except for rs6706648 and rs7606173 where the MAFs were 0.4 and 0.44 in African 
American and 0.11 and 0.25 in Saudi cases. To examine the effect of rs1427407, 
rs6706648, and rs7606173 we examined the distribution of HbF levels by the genotypes 
of these SNPs. We took advantage of the phased imputed data to examine the three SNPs 
haplotype effect on HbF. Homozygosity for a TCG haplotype of rs1427407, rs6706648 
and rs7606173, respectively, was associated with 10 % HbF in African American 
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patients. This haplotype was found in 29% of Saudi and 24% of African American Benin 
haplotype patients. Homozygosity for the T allele rs1427407 was always associated with 
homozygosity for the C allele of rs6706648 and G allele of rs7606173. Homozygosity for 
a GTC haplotype of these same three SNPs was associated with 4.5% HbF in African 
American Benin and had a frequency of 0.40 in African American Benin, and 0.11 in 
Saudi Benin patients. Even when accounting for the population frequency differences of 
the TCG and GTC haplotypes, BCL11A variants do not explain the difference in HbF 
level seen between Saudi Benin and African America Benin sickle cell anemia. 
 
A 3-base pair deletion in the HBS1L-MYB intergenic region is likely to be the functional 
element accounting for increased HbF associated with this QTL and is in high LD with 
rs9399137 (Farrell et al. 2011). The MAF of this SNP was 0.037 and 0.047 in Saudi 
Benin and African American Benin patients respectively suggesting that the 3-bp deletion 
is unlikely to explain the HbF difference between Saudi Benin and African American 
Benin patients. 
 
The difference in HbF between Saudi Benin and African Americans Benin may due to 
one or more variants in Saudi Benin patients that could not be detected due to the small 
number of cases available for study. Whole genome sequencing might help identify 
genetic differences between these populations that account for their disparate HbF levels. 
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Figure 6. Manhattan plot for Saudi Benin haplotype and HbF. There is no signal at 
chromosome 2 which corresponds to BCL11A SNPs. 
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Figure 7. Manhattan plot for African American Benin haplotype and HbF. There is a 
clear signal at chromosome 2 which corresponds to BCL11A SNPs. 
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CHROM	 BEGIN	 END	 MARKER_ID	 NS	 MAF	 PVALUE	 BETA	
1	 5504553	 5504553	 1:5504553_G/A_Intergenic	 63	 0.2381	 9.74E-07	 -0.19241	
9	 97412837	 97412837	 9:97412837_C/T_Intergenic	 63	 0.16667	 1.47E-06	 0.22112	
3	 9067668	 9067668	 3:9067668_C/T_Intron:SRGAP3	 63	 0.14286	 1.84E-06	 0.24474	
1	 5489136	 5489136	 1:5489136_C/T_Intergenic	 63	 0.34921	 1.88E-06	 -0.17445	
1	 44630318	 44630318	 1:44630318_C/T_Intergenic	 63	 0.29365	 2.18E-06	 -0.17355	
1	 5488947	 5488947	 1:5488947_GA/G_Intergenic	 63	 0.36508	 2.46E-06	 -0.15751	
1	 5516961	 5516961	 1:5516961_T/A_Intergenic	 63	 0.34921	 3.25E-06	 0.15378	
1	 44633681	 44633681	 1:44633681_C/T_Intergenic	 63	 0.28571	 4.26E-06	 -0.17587	
1	 44745624	 44745624	 1:44745624_C/T_Intron:ERI3	 63	 0.31746	 5.48E-06	 -0.16997	
1	 44751206	 44751206	 1:44751206_A/G_Intron:ERI3	 63	 0.31746	 5.48E-06	 -0.16997	
 
Table 8. Top associations with HbF in Saudi patients homozygous for the Benin 
haplotype with MAF = [0.05,0.5]. NS denotes number of samples and BETA represents 
the effect of a SNP. 
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CHR BEGIN END RSID MARKER_ID NS MAF PVALUE BETA 
2 60718043 60718043 rs1427407  2:60718043_T/G_Intron:BCL11A 293 0.25 5.44E-08 -0.20 
2 60722040 60722040 rs6706648 2:60722040_C/T_Intron:BCL11A 293 0.40 2.61E-07 -0.16 
22 33862330 33862330 rs557939075 22:33862330_G/GT_Insertion:LARGE 293 0.12 3.05E-07 -0.25 
2 60725451 60725451 rs7606173 2:60725451_G/C_Intron:AC009970.1|BCL11A 293 0.44 5.13E-07 -0.16 
2 60724086 60724086 rs1896295 2:60724086_T/C_Intron:AC009970.1|BCL11A 293 0.27 7.52E-07 -0.18 
2 60724087 60724087 rs1896296  2:60724087_G/T_Intron:AC009970.1|BCL11A 293 0.27 7.52E-07 -0.18 
6 11287332 11287332 rs4713339 6:11287332_C/T_Intron:NEDD9 293 0.23 7.93E-07 -0.18 
3 196544117 196544117 rs13080125 3:196544117_T/C_Intron:PAK2 293 0.35 8.29E-07 0.16 
2 60719970 60719970 rs766432 2:60719970_C/A_Intron:BCL11A 293 0.27 8.97E-07 -0.18 
2 60720951 60720951 rs4671393 2:60720951_A/G_Intron:BCL11A 293 0.27 8.97E-07 -0.18 
 
Table 9. Top associations with HbF in African Americans homozygous for the Benin 
haplotype with MAF = [0.05,0.5]. NS denotes number of samples and BETA represents 
the effect of a SNP. 
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Chapter 4. Investigating Cis- and Trans-Acting Regulators of HbF Expression 
Using GTEx 
 
Background 
GWAS and genetics studies have detected many SNPs in chromosomes 2, 6, and 11 that 
were associated with HbF levels in normal individuals and in patients with sickle cell 
anemia and b thalassemia (Bhanushali et al. 2015; Craig et al. 1996; Garner et al. 1998; 
Mtatiro et al. 2014; Solovieff et al. 2010; Thein et al. 1987; Uda et al. 2008). These 
studies used either HbF protein levels (expressed as a percentage of total hemoglobin 
levels) or the percentage of all erythrocytes that were F-cells (erythrocytes containing 
sufficient HbF to be detected by immunofluorescence) as a quantitative trait. HbF is a 
tetramer composed of two a and two g polypeptide subunits. The g-globin subunits, 
which characterize HbF, are encoded by two closely linked genes, from 5’ to 3’, HBG2 
and HBG1. The respective polypeptides of the g-globin genes differ by only a single 
amino acid in position 136; glycine the Gg chain (HBG2) and alanine in the Ag chain 
(HBG1) (Schroeder et al. 1968). In adults, these genes are expressed at a ratio of 2:3 
(Terasawa et al. 1980). The differential expression of these  g-globin genes might provide 
an understanding of whether the expression quantitative trait loci (eQTL) associated with 
HBG expression affect the expression of one or both genes and therefore, provide 
additional insight into their mechanisms of action. eQTLs are genomic loci that lead to 
variability in mRNAs expression levels. Analyzing HBG2 and HBG1expression 
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separately should allow the detection of eQTLs that affect the expression of a single or 
both g-globin genes.  
 
RNA sequence, whole genome sequences, or genotypes from erythroid progenitor cells 
expressing HBG would provide the ideal data set to study cis and trans-acting elements 
that regulate HbF expression. However, such a data set is not publicly available. The 
Genotype-Tissue Expression (GTEx) -project provides an alternative resource to study 
HbF gene expression, the regulatory elements modulating HBG (both g-globin genes) 
expression, and any effects of genetic variation in these regulatory elements on HBG 
expression (GTEx_Consortium 2013).The GTEx project was launched in 2010 by the 
National Institute of Health (NIH) to create a publicly available database and tissue bank. 
The GTEx samples are either from deceased organ/tissue or surgical donors.  GTEx 
contains RNA sequencing data and genome-wide SNP analysis from multiple human 
tissues. These tissues include peripheral blood that contains reticulocytes that express 
hemoglobin genes and synthesize about 10% of total hemoglobin. The primary limitation 
of using GTEx data is that the blood samples obtained were likely to have reticulocyte 
counts of <1% of total red cells. However, reticulocytes are the only cells in the blood 
that express hemoglobin genes. eQTLs can be identified by analyzing global RNA 
expression using the expression levels of genes as quantitative phenotypes.  
 
We performed a genome-wide association study (GWAS) to detect eQTLs associated 
with expression of HBG in whole blood, other genes of the b-globin (HBB) gene cluster 
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and with known HbF cis- and trans-acting regulators. In addition, we examined genes co-
expressed with HBG1 to discover enriched pathways, studied upstream regulators of HbF 
co-expressed genes and performed correlation analysis between HBG and known HbF 
regulators. A similar correlation analysis included BCL2L1, a potential HbF activator we 
found in our analysis. We hypothesized that trans-acting elements that are transcription 
factors affect the expression of both HBG2 and HBG1, while the known cis-acting QTL 
in the promoter of HBG2 is likely to be associated with the expression of this gene only.  
 
Methods 
Genome-wide eQTL association analysis 
Whole blood normalized RNA-seq data, 1000 Genome imputed genotypes, and the 
covariates file of 338 donors were downloaded from the GTEx portal version 6. The 
covariates used in the original GTEx data analysis included 3 genome-wide genotype 
principal components (PCs), 35 Probabilistic Estimation of Expression Residuals (PEER) 
factors to be used as confounders, genotyping platform (Illumina HiSeq 2000 or HiSeq 
X), and sex (Consortium 2017). We performed genome-wide eQTL analysis using 
Efficient and Parallelizable Association Container Toolbox (EPACTS) (EPACTS 2017) 
and selected SNPs with minor allele frequency (MAF) ≥ 0.01 and imputation quality 
score (R^2) ≥ 0.4 to reduce the rate of false association. We used the first 3 PCs to adjust 
for population substructure. We also used sex and platform as covariates to remove any 
bias introduced by these two components. The 35 PEER factors were used to adjust for 
batch effects and experimental confounders. This standard set of covariates were used in 
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the models to detect eQTLs for HBG1, HBG2, BCL11A, KLF1, MYB, HBB, and HBD.  
To detect any significant association after adjusting for the most significant SNPs on 
chromosomes 2, 6, and 11, we tested association of normalized expression of HBG1 and 
HBG2 conditioned on the genotypes of rs7482144, rs1427407, and rs66650371. Only 
SNPs that reached genome-wide significance level of p-value ≤ 5 × 10-8 were considered 
statistically significant. 
 
Preliminary studies 
To reproduce the genetic association of known QTL variants with HBG expression using 
GTEx RNA-seq data from reticulocytes, three SNPs were selected based on their prior 
association with HbF levels in GWAS. We chose rs1427407 in the BCL11A erythroid-
specific enhancer on chromosome 2p (Bauer et al. 2013), rs10128556, which is in high 
linkage disequilibrium (LD) with the Xmn1 restriction polymorphism (rs7482144) on 
chromosome 11p  (Galarneau et al. 2010), and rs9399137 that is in perfect LD with the 3-
base pair deletion (rs66650371) in the HBS1L-MYB intergenic polymorphisms (HMIP) 
region on chromosome 6q (Farrell et al. 2011). SNPs in LD with rs66650371and 
rs7482144 were chosen because GTEx pre-calculated eQTL did not contain these SNPs. 
The GTEx eQTL calculation tool was used to validate these associations in 338 whole 
blood samples available in the GTEx portal. We sought to validate the effect of a 
BCL11A erythroid-specific-enhancer SNP on HBG2 and HBG1 to confirm that genotype 
can be used to predict phenotype and vice versa.  
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Association of the erythroid-specific BCL11A enhancer variant rs1427407 with whole 
blood gene expression 
We extracted the genotype of rs1427407 form GTEx data set version 6 and used these 
data to predict the impact of this SNP on global gene expression. The same covariates 
were used in the eQTL analysis, and Linear Models for Microarray and RNA-seq Data 
(limma) were used to perform linear regression (Ritchie et al. 2015). We used false 
discovery rate (FDR) to correct for multiple hypothesis testing. 
 
HBG1 differential co-expression analysis 
Since HBG2 expression is significantly associated with the genotype of rs7482144, we 
used HBG1 expression as a marker of expression of both g-globin genes. A gene 
expression matrix of normalized log expression of RNA-seq along with covariates 
including 35 PEER factors and sex from 338 whole blood samples were used as input for 
limma to perform differential analysis. We used FDR to correct for multiple testing. 
Using Ingenuity Pathways Analysis (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) we 
performed pathway analysis using the top100 co-expressed genes to see whether there 
was any enrichment in pathways involved in HbF regulation. In addition, we examined 
upstream regulators of the genes in the top100 HBG1 co-expressed gene list to identify 
HbF transcriptional regulators 
that can explain the observed gene expression changes. 
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Correlation analysis between known and potential HbF regulators and HBG 
expression 
We performed Pearson correlation between HBG expression and the expression of 
BCL11A, KLF1, MYB, ZBTB7A, SIRT1 and BCL2L1 on 338 GTEx whole blood samples. 
These genes were selected because of their role or putative role as modulators of HBG 
expression, except for BCL2L1 which was selected based on our HBG1 co-expression 
and upstream regulators analysis (Dai et al. 2017; Jiang et al. 2006; Masuda et al. 2016; 
Zhou et al. 2010).  
 
To replicate parts of our GTEx-based analysis, the same correlation analysis was done on 
data from erythroid samples acquired from Gene Expression Omnibus (GEO; accession 
number GSE59089) (Xu et al. 2015). These data contained RNA-seq derived from 
primary human fetal liver proerythroblasts studied at different developmental stages after 
shRNA-mediated knockdown of Polycomb Repressive Complex 2 (PRC2) core subunits.  
 
Results 
Preliminary studies 
GTEx whole blood RNA-seq data detected HbF eQTLs in BCL11A, HMIP and in the 
HBB gene cluster using HbF gene expression as a surrogate for HbF protein levels, 
validating the utility of this data set for examining HbF-associated eQTL (Table 10 and 
Fig. 8A-F).  
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Genome-wide eQTL association analysis 
 Twenty-seven SNPs were eQTL associated with HBG1 (p-value <= 5 × 10−8). Of these 
27, 21 were intergenic variants in the HMIP region on chromosome 6p, five were 
BCL11A variants on chromosome 2p, and one was on chromosome 11p (Fig. 9A, Table 
S1). The SNP rs66650371, the functional 3-bp deletion in the MYB enhancer, is one of 
the most significant SNPs in the HMIP region. The most significant SNP of the five 
BCL11A variants was rs1427407, which in other studies was the functional SNP in the 
erythroid-specific enhancer of this gene (Bauer et al. 2013). 
 
Forty-nine SNPs meeting genome-wide significance levels were eQTL for HBG2.  
Seventeen were intergenic variants in the HMIP region on chromosome 6, five were 
BCL11A variants on chromosome 2p, 26 were on chromosome 11p (Fig 9B, Table S2) 
and one was on chromosome 1. The most significant SNP in chromosome 11 was 
rs7482144 and this was associated only with the expression of HBG2; rs16912979, which 
is located in hypersensitive site (HS) 4 of the locus control region (LCR) of the HBB gene 
complex, was also associated solely with HBG2 expression. The SNP rs66650371 (MYB) 
and rs1427407 (BCL11A) were significantly associated with both HBG2 and HBG1.  The 
conditional analysis of HBG1 showed that after adjusting for the effects of rs1427407, 
rs66650371, and rs7482144, there was no association on chromosome 2 or chromosome 
6 (Fig. 9C, Table S3). 
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Conditional analysis of HBG2 showed that no SNP was significantly associated with 
HBG2 expression after adjusting for rs7482144, rs1427407, and rs66650371 (Fig. S1, 
Table S4). There was no SNP with genome-wide significance associated with expression 
of BCL11A and ZBTB7A (Figs. S2, S3; Tables S5, S6). One SNP on chromosome 6 was 
associated with MYB expression, another on chromosome 6 was associated with HBD 
expression, and one on chromosome 12 was associated with KLF1 expression (Figs. S4, 
S5, S6; Tables S7, S8, S9). Variants on chromosome 1, 2, 6, 7, 14, and 20 were 
significantly associated with HBB expression (Fig. S7, Table S10). 
 
Association of the erythroid-specific BCL11A enhancer variant rs1427407 with whole 
blood gene expression 
Linear regression analysis showed that the genotype of rs1427407 was significantly 
associated with HBG1 and HBG2 expression in whole blood (Table 11) after correction 
for multiple testing using FDR, p-values were 2.04E-06 and 3.63E-06 for HBG1 and 
HBG2, respectively. This SNP was not a eQTL for any other gene expressed in peripheral 
blood. 
 
HBG1 differential co-expression analysis 
Twelve genes were differentially co-expressed with HBG1 after FDR p-value adjustment 
(Table S11). The pathway enrichment analysis for the top100 co-expressed genes did not 
include any known pathway involved in HbF regulation among the top 10 enriched 
pathways. Of 452 upstream regulators that regulate the top100 HBG1 co-expressed 
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genes, 360 regulated BCL2L1 (Table S12). GATA1and KLF1 were also in top five 
statistically significant upstream regulators.  
 
Correlation analysis between known and potential HbF regulators and HBG 
The correlation between HBG1 and HBG2 normalized gene expression and the 
expression of BCL11A, KLF1, MYB, ZBTB7A, SIRT1 and BCL2L1 in the GTEx whole 
blood data set, showed that BCL2L1 had correlation coefficients of 0.59 and 0.55 for 
HBG1 and HBG2, respectively with a p value of 2.2E-16. (Table 12).   
 
In primary human fetal liver proerythroblasts, BCL2L1, KLF1, and SIRT1 were positively 
correlated with HBG expression with correlation coefficients of 0.93, 0.92, and 0.62, 
respectively; BCL11A and MYB were negatively correlated with HBG1 with correlation 
coefficients of -0.63, and -0.64, respectively; ZBTB7A was weakly correlated with HBG1, 
and the p-value for association was not significant (Table 13).     
 
Discussion 
Among eQTL significantly associated with HBG expression 21 were intergenic variants 
in HMIP on chromosome 6p. The functional 3-bp deletion (rs66650371) was one of the 
most significant eQTL in this MYB enhancer (Farrell et al. 2011; Stadhouders et al. 
2014). The SNP rs66650371 was in strong LD with 20 other SNPs in chromosome 6p in 
Europeans, South and East Asians, and admixed Americans (Table S13). A long non-
coding or lncRNA containing the site of rs66650371was transcribed from this enhancer. 
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Its downregulation in an erythroid cell line that expressed adult hemoglobin (HbA) was 
associated with a 200-fold increase in HBG expression and a 20-fold increase in HbF 
(Morrison et al. 2017). The eQTL at rs66650371 further supports the functional 
importance of this SNP.  Five BCL11A SNPs in chromosome 2p were in very strong LD 
across populations (Table S14). The most significant, rs1427407, is a functional 
erythroid-specific enhancer variant that altered the expression of BCL11A (Bauer et al. 
2013). Both rs1427407 and rs66650371are trans-acting elements and had the same 
magnitude of effect on HBG1 and HBG2 (Fig. 8C, 8D; Fig. 10). These observations are 
consistent with our hypothesis that trans-acting elements affect expression of both g-
globin genes. 
The SNP rs10128556 in the pseudogene HBBP1 on chromosome 11p was in strong LD 
with rs7482144 and was reported to have an effect independent of rs7482144 in African 
American sickle cell disease patients and be the likely functional variant modulating cis-
acting HbF gene expression (Galarneau et al. 2010). However, rs7482144 is located 
within the HBG2 promoter and highly linked to rs368698783 in HBG1 promoter.  The 
SNP rs368698783 together with rs7482144 are associated with reduced methylation in 
six CpG sites flanking the transcription start site of HBG (Chen et al. 2017). Moreover, 
rs7482144 alters a putative binding motif for ZBTB7A, a silencer of HBG expression 
(Masuda et al. 2016; Shaikho et al. 2016).  
 
Strong evidence supporting differential regulation of HBG by cis- and trans-acting 
elements comes from clinical observations of patients with the Arab Indian (AI) and 
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Senegal haplotypes of the sickle hemoglobin (HbS) gene and from the reports of 
hereditary persistence of HbF (HPFH) caused by point mutations in HBG promoters. 
Patients with the AI and Senegal haplotypes, which are the only HBB haplotypes 
containing rs7482144, had increased levels of HbF that was predominantly of the Gg-
globin type (Ballas et al. 1991; Nagel et al. 1985; Rahimi et al. 2015). Many mutations 
have been described in the promoters of HBG2 and HBG1 that cause the phenotype of 
HPFH. For each of these mutations, depending on the affected gene, either HBG2 or 
HBG1usually comprises more than 90% of total g globin (Wood 2001). The T-C 
mutations at -175 and -173 in the promoter of HBG1 reactivated Ag-globin gene 
expression in adult erythrocytes of transgenic mice while altering the binding of GATA-1 
and Oct-1 and (Liu et al. 2005). Moreover,  a C-T polymorphism that is identical to 
rs7482144 but at position -158 relative to HBG1 affected HBG1 expression (Patrinos et 
al. 1998).  
These results suggest that rs7482144 rather than rs10128556 is either the functional cis-
acting element regulating HBG2 expression or the best surrogate for this element. In 
addition, rs16912979 in HS-4 of the LCR is also solely associated with HBG2 further 
supporting the effect of cis-acting elements on a single g-globin gene (Fig. 11, 12). This 
SNP is a member of the 3-SNP T/A/T haplotype (rs16912979, rs7482144, rs10128556) 
that is exclusive to the AI haplotype and is associated with their high HbF (Vathipadiekal 
et al. 2016). The T allele of rs16912979 tags a predicted binding site for runt-related 
transcription factor 1 (RUNX1) in the palindromic region of 5′ HS-4.  RUNX1 plays an 
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important role in hematopoiesis and electromobility shift assays (EMSA) suggested an 
allele-specific binding of RUNX1 to 5′ HS-4 (Dehghani et al. 2016). 
 
No common variants affected the expression of BCL11A. The BCL11A hypersensitive 
site variant rs1427407 is erythroid specific and in whole blood samples would impact 
BCL11A expression only in reticulocytes.  However, BCL11A is expressed in leukocytes 
that are abundant in the blood. BCL11A expression in these nucleated cells with their 
greater transcriptional activity than reticulocytes would render an erythroid-specific 
signal impossible to detect. Our inability to find genes known to influence HBG1 in the 
co-expression analysis and a lack of correlation of known HbF regulators with HBG in 
GTEx data despite a strong relationship in fetal liver proerythroblasts might have a 
similar explanation and illustrate the main limitation of using GTEx data where globin 
synthesizing reticulocytes were likely to be  <1% of all red blood cells(Means RT 2009). 
Although few in number, reticulocytes are the only cells in the blood expressing globin 
genes, and RNA-seq provides sufficient data for most statistical analysis.  
 
The unexpected correlation between BCL2L1 and HBG expression (r 0.58 & 0.55; 
p=2.30E-16) was validated in fetal proerythroblasts (r> 0.9). BCL2L1 is a member of bcl-
2 gene family involved in anti-apoptotic activities with an important role in 
erythropoiesis. Induction of bcl-xL (BCL2L1) expression by erythropoietin and GATA1 
was critical for the survival of late proerythroblasts and early normoblasts (Gregory et al. 
1999).The upstream regulation analysis shows that BCL2L1 was regulated by 80 percent 
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of the regulators that regulate the top 100 co-expressed genes. GATA1 and KLF13 are 
among these upstream regulators. These data and the correlation of BCL2L1 with HBG 
suggest a role for BCL2L1 in HbF regulation. Experimental validation to confirm the 
relationship between BCL2L1 and HBG and to pinpoint the mechanism through which 
BCL2L1 regulates HBG expression could lead to the discovery of potential new drug 
targets or molecules that can be used to induce HbF in sickle cell anemia and b 
thalassemia. 
 
Cis- and trans-acting regulators have a differential effect on HBG1 and HBG2 
expression. The trans-acting eQTLs of BCL11A and MYB enhancers affect expression of 
both g-globin genes. In contrast, only a single  g-globin gene is affected by the cis-acting 
eQTL. HbF is the major modulator of the severity of both sickle cell anemia and b 
thalassemia and considerable effort is being made to develop methods to increase HBG 
expression for therapeutic gain (Deng et al. 2014; Lettre and Bauer 2016). Although 
clinical observations suggest that an increase of HBG2 alone has some benefit (Alsultan 
et al. 2014; Ballas et al. 1991; Teixeira et al. 2003), modification of trans-acting elements 
that affect both HbF genes might have a greater effect on HbF levels and help force a 
more pancellular distribution that could be therapeutically important (Guda et al. 2015; 
Masuda et al. 2016; Sankaran et al. 2011; Steinberg et al. 2014). 
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Figure 8. Effect of rs1427407 (2:60718043_T/G), rs10128556 (11:5263683_C/T), and 
rs9399137 (6:135418632_TTAC/T) on HBG1 and HBG2 expression in GTEx data set 
version 6. P-values are above genome-wide significance for rs1427407 (BCL11A, chr2) 
and rs9399137 (MYB, chr6) association with expression of both HBG genes. 
Rs10128556 (chr 11) is significantly associated with only HBG2 (p-value of 2.60E-16) 
while it has no effect on HBG1(p-value 0.89) Het denotes heterozygous, and Homo, 
homozygous. 
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Figure 9. Manhattan plots for HBG eQTLs in 338 whole blood samples. Fig. 9A shows 
HBG1 eQTL; Fig. 9B shows HBG2 eQTL; Fig. 9C shows HBG1 eQTL conditioned on 
rs66650371, rs1427407 and rs7482144 genotype. The red line indicates genome-wide 
significance levels 
A 
B
 
C 
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Figure 10. Effect of rs66650371 (6:135418632_TTAC/T) genotypes on HBG1 and HBG2 
expression in 338 whole blood samples. P-values of genome-wide association are 6.49E-
11 and 5.86E-09 for HBG1 and HBG2, respectively. 
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Figure 11. Effect of rs16912979 (11_5309695_T_C) on HBG2 and HBG1 expression in 
GTEx data set. p-values of genome-wide significance are 7.0e-14 and 0.77, respectively. 
Het denotes heterozygous, and Homo, homozygous. 
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Figure 12. Effect of rs7482144 (11:5276169_G/A) genotypes on HBG1 and HBG2 
expression in 338 whole blood samples. P-values of genome-wide association are 
0.038593 and 9.49E-16 for HBG1 and HBG2, respectively. 
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Gene	Symbol	 Variant	Id	 SNP	 P-Value	 Effect	Size	 T-Statistic	 Standard	Error	
HBG1	 2_60718043_T_G_b37	 rs1427407	 1.20E-11	 -0.46	 -7.1	 0.065	
HBG1	 11_5263683_C_T_b37	 rs10128556	 0.89	 -0.0085	 -0.14	 0.059	
HBG1	 6_135419018_T_C_b37	 rs9399137	 2.20E-15	 0.51	 8.4	 0.061	
HBG2	 2_60718043_T_G_b37	 rs1427407	 1.10E-09	 -0.46	 -6.3	 0.073	
HBG2	 11_5263683_C_T_b37	 rs10128556	 2.60E-16	 0.51	 8.7	 0.058	
HBG2	 6_135419018_T_C_b37	 rs9399137	 1.70E-09	 0.44	 6.2	 0.07	
 
 
Table 10. SNPs from previous GWAS and their association with HBG1 and HBG2 
expression in whole blood samples available in the GTEx portal. 
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ENS_ID Gene Symbol logFC AveExpr P.Value adj.P.Val 
ENSG00000213934.5 HBG1 0.502491942 -4.32E-06 8.51E-11 2.04E-06 
ENSG00000196565.8 HBG2 0.507932715 -7.56E-06 3.03E-10 3.63E-06 
ENSG00000187017.10 ESPN 0.307905604 -1.45E-07 1.80E-05 0.143668299 
ENSG00000239405.1 TMED10P2 0.362195583 0.002468525 7.07E-05 0.423972382 
ENSG00000010626.10 LRRC23 0.277170914 2.20E-07 9.30E-05 0.427249648 
ENSG00000248309.1 MEF2C-AS1 0.320432287 -9.14E-08 0.000106933 0.427249648 
ENSG00000160401.10 CFAP157 -0.342869883 -8.98E-07 0.000164101 0.561998024 
ENSG00000135414.5 GDF11 -0.163176468 -3.51E-08 0.000286461 0.777799594 
ENSG00000255318.1 - -0.358828046 0.000665361 0.000316391 0.777799594 
 
Table 11. Effect of rs1427407 on whole blood gene expression. ENS_ID is ensemble 
gene ID, LogFC is log fold change, aveExpr is average expression, and adj.P.Val is FDR 
adjusted p-value. 
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Regulators	 HBG1	Correlation	 P-value	 HBG2	Correlation	 P-value	
BCL2L1	 0.59	 2.20E-16	 0.55	 2.20E-16	
KLF1	 0.47	 2.20E-16	 0.44	 2.20E-16	
MYB	 0.27	 2.94E-07	 0.27	 2.8E-07	
BCL11A	 0.15	 0.003914	 0.17	  0.001694	
SIRT1	 -0.06	 0.238	 -0.06	 0.29	
ZBTB7A	 -0.0045	 0.9334	 0. 067	 0.212	
 
 
 
Table 12. Pearson correlation between HBG and known or potential HbF regulators using 
RNA-seq from 338 whole blood samples from GTEx.  
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Regulators	 HBG1	Correlation	 P-value	 HBG1	Correlation	 P-value	
BCL2L1	 0.93	 3.85E-07	 0.93	 3.85E-07	
KLF1	 0.92	 9.24E-07	 0.92	 9.24E-07	
MYB	 -0.64	 0.01	 -0.63	 0.01	
BCL11A	 -0.63	 0.01	 -0.63	 0.01	
SIRT1	 0.62	 0.01	 0.62	 0.01	
ZBTB7A	 -0.38	 0.17	 -0.38	 0.16	
 
Table 13. Pearson correlation between HBG and known or potential HbF regulators using 
RNA-seq primary human fetal liver proerythroblasts. 
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Chapter 5. Conclusion 
 
A phased SNP-based classification of sickle cell anemia HBB haplotypes 
The main advantage of the phased SNP-based haplotype determination method is the 
rapid classification and high accuracy. This method can also be used for whole genome 
sequence data classification after SNP calling and phasing. Moreover, it is not sensitive 
to SNPs that alter the restriction enzyme recognition sequence that can lead to error using 
RFLPs. A limitation of the phased SNP-based haplotype determination method is the 
dependency on the availability of GWAS data for many SNPs in the β-globin gene 
region. However, the cost of genome-wide SNP arrays has fallen dramatically and 
haplotype ascertainment by GWAS is likely to be less expensive than traditional 
methods. Also, patient cohorts with genome-wide SNP array data or whole genome 
sequencing data are increasing available. The method is very fast and more accurate than 
the RFLP method and very useful in generating haplotype information that can be used as 
a covariate in a genetic risk analysis. 
 
Genetic Determinants of HbF in Saudi Arabian and African Benin Haplotype Sickle 
Cell Anemia 
Based on the GWAS analysis for Saudi and African American Benin haplotype, 
homozygosity for a BCL11A enhancer haplotype of T (rs1427407), C (rs6706648) and G 
(rs7606173) in the enhancer elements +62, +58 and +55, was associated with 10 % HbF 
in African American. Homozygosity for the GTC haplotype of these same three SNPs 
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was associated with 4.5% HbF in African American Benin and had a frequency of 0.40 in 
African American Benin, and 0.11 in Saudi Benin patients. In another study that used 
focused  genotyping of the BCL11A enhancer SNPs, enhancer haplotypes associated with 
lower HbF were almost three times as common in the African Benin haplotype compared 
with the Saudi Benin haplotype (Sebastiani et al. 2015). Even when accounting for the 
population frequency differences of BCL11A enhancer and the 3-base pair deletion in the 
HBS1L-MYB intergenic polymorphisms (HMIP) haplotypes, BCL11A and HMIP variants 
did not explain the difference in HbF levels in Saudi Benin and African America Benin 
sickle cell anemia. The small number of Saudi Benin haplotype cases studied diminished 
the power of this study to find novel associations, particularly if the minor allele 
frequency was low and the effects of the variant on HbF were small. 
 
Cis and Trans-Acting Regulators of HbF Expression 
A sub-haplotype of rs16912979, rs7119428, and rs7482144 of the seven SNPs located 
within putative ZBTB7A binding motifs differentiates AI, Senegal, and Benin 
haplotypes. Homozygosity for minor alleles at rs16912979, rs7119428, and rs7482144 
(T/A/T) is exclusive to the AI haplotype, and this sub-haplotype might represent a 
functional cis-acting domain modulating HBG2 expression. Rs16912979 in the HS-4 
region has strong binding signals for GATA1, GATA2, and POLR2A. Senegal haplotype 
carriers are homozygous for the T allele of rs7482144 but do not have the minor allele of 
rs16912979 and rs7119428 (C/C/T), while Benin haplotype is (C/C/C). Perhaps this 
divergence accounts in part for the differences in HbF between Senegal and AI 
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haplotypes. In summary, SNPs in putative ZBTB7A binding sites distinguish the AI 
haplotype from African-origin HBB haplotypes. As these variants are present in regions 
with characteristics of active enhancers, like transcription factor binding and epigenetic 
marks, they are candidates for the functional elements of this haplotype. Perhaps this 
haplotype alters looping of the LCR to globin gene promoters. It must be emphasized 
however that mechanistic studies are required to prove the functionality of these variants.  
 
eQTL analysis of g-globin genes expression suggests a differential effect of cis- and 
trans-acting HbF regulators. The trans-acting eQTLs (rs1427407 in the BCL11A enhancer 
and the HMIP eQTL rs66650371) influence the expression both HBG genes; cis-acting 
eQTLs (rs7482144 and rs16912979) on chromosome 11) only affect HBG2. 
 
The strong correlation between BCL2L1 and HBG expression in the validation data set 
(primary human fetal liver proerythroblasts) and the upstream regulation analysis suggest 
that BCL2L1 is a potential new HbF regulatory element. 
 
Current Work and Future Directions 
 
To begin further studies on the effects of BCL2L1 on HBG expression we examined 
expression levels of this gene and percent HbF in sickle cell anemia.  HbF expression was 
obtained by qRT-PCR analysis of mRNA isolated from cultured erythroid progenitor 
cells from eight patients. The preliminary results show a good correlation between 
BCL2L1 mRNA and HBG mRNA (R2 0.72, p <0.05).  
  
65 
 
These promising preliminary studies suggest future work aimed at experimental and 
functional validation of BCL2L1 and its effect on HBG, and the mechanism through 
which BCL2L1 regulates HbF gene expression. Using such methods as overexpression 
and knockdown of BCL2L1 in primary erythroid progenitors and cell lines that synthesize 
adult and fetal hemoglobins will help us better define and understand the role of this gene 
in modulating HBG expression and possibly targeting this gene for therapeutic purposes.
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